Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07232069 · ClinicalTrials.gov registry record · Phase 3
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
A Phase 3 study, sponsored by Duke University.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,500
- Enrollment target
NCT07232069: Clinical Trial Phase 3 study, sponsored by Duke University.
NCT07232069 is a Phase 3 study that has not yet begun recruiting, run by Duke University. The registered enrollment target is 1,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07232069, a Phase 3 study, has not yet begun recruiting, sponsored by Duke University.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,500 participants
- Enrollment target
Study Summary
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works. PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases: 1. A Screening Study - Participants will be assessed for plaque by one or both of these scans. * Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries. * Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque. 2. A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos. * Rosuvastatin 20 mg: a cholesterol-lowering medicine * Colchicine 0.5 mg: a medication that lowers inflammation Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle. Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Primary Outcome
Plaque volume in mm3 in each group
Interventions
- DRUG Placebo
- DRUG Rosuvastatin 20 Mg Oral Tablet
- DRUG Colchicine 0.5 MG Oral Tablet Once Daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2031-07 |
| Phase | Phase 3 |
What is known before NCT07232069 opens enrollment
NCT07232069 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07232069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07232069 about?
NCT07232069 is a clinical study titled "PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis". Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works. PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart ...
What is the current status of trial NCT07232069?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2026-07-01. Estimated completion is 2031-07.
What interventions are being tested in trial NCT07232069?
The interventions under investigation include: Placebo (DRUG), Rosuvastatin 20 Mg Oral Tablet (DRUG), Colchicine 0.5 MG Oral Tablet Once Daily (DRUG).
Who is sponsoring clinical trial NCT07232069?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07232069's enrollment target sits among peer trials
1,500 158th of 2000 higher than 1,838 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI